Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 142

1.

A prospective ascertainment of cancer incidence in sub-Saharan Africa: The case of Kaposi sarcoma.

Semeere A, Wenger M, Busakhala N, Buziba N, Bwana M, Muyindike W, Amerson E, Maurer T, McCalmont T, LeBoit P, Musick B, Yiannoutsos C, Lukande R, Castelnuovo B, Laker-Oketta M, Kambugu A, Glidden D, Wools-Kaloustian K, Martin J.

Cancer Med. 2016 May;5(5):914-28. doi: 10.1002/cam4.618. Epub 2016 Jan 28.

2.

Incidence rate of Kaposi sarcoma in HIV-infected patients on antiretroviral therapy in Southern Africa: a prospective multicohort study.

Rohner E, Valeri F, Maskew M, Prozesky H, Rabie H, Garone D, Dickinson D, Chimbetete C, Lumano-Mulenga P, Sikazwe I, Wyss N, Clough-Gorr KM, Egger M, Chi BH, Bohlius J.

J Acquir Immune Defic Syndr. 2014 Dec 15;67(5):547-54. doi: 10.1097/QAI.0000000000000360.

3.

Kaposi's Sarcoma in HIV-infected patients in South Africa: Multicohort study in the antiretroviral therapy era.

Bohlius J, Valeri F, Maskew M, Prozesky H, Garone D, Sengayi M, Fox MP, Davies MA, Egger M.

Int J Cancer. 2014 Dec 1;135(11):2644-52. doi: 10.1002/ijc.28894. Epub 2014 May 2.

4.

Immune reconstitution inflammatory syndrome associated with Kaposi sarcoma: higher incidence and mortality in Africa than in the UK.

Letang E, Lewis JJ, Bower M, Mosam A, Borok M, Campbell TB, Naniche D, Newsom-Davis T, Shaik F, Fiorillo S, Miro JM, Schellenberg D, Easterbrook PJ.

AIDS. 2013 Jun 19;27(10):1603-13. doi: 10.1097/QAD.0b013e328360a5a1.

PMID:
23462220
5.

Pitfalls of practicing cancer epidemiology in resource-limited settings: the case of survival and loss to follow-up after a diagnosis of Kaposi's sarcoma in five countries across sub-Saharan Africa.

Freeman E, Semeere A, Wenger M, Bwana M, Asirwa FC, Busakhala N, Oga E, Jedy-Agba E, Kwaghe V, Iregbu K, Jaquet A, Dabis F, Yumo HA, Dusingize JC, Bangsberg D, Anastos K, Phiri S, Bohlius J, Egger M, Yiannoutsos C, Wools-Kaloustian K, Martin J.

BMC Cancer. 2016 Feb 6;16:65. doi: 10.1186/s12885-016-2080-0.

6.

Updating vital status by tracking in the community among patients with epidemic Kaposi sarcoma who are lost to follow-up in sub-Saharan Africa.

Semeere A, Freeman E, Wenger M, Glidden D, Bwana M, Kanyesigye M, Asirwa FC, Rotich E, Busakhala N, Oga E, Jedy-Agba E, Kwaghe V, Iregbu K, Adebamowo C, Jaquet A, Dabis F, Phiri S, Bohlius J, Egger M, Yiannoutsos CT, Wools-Kaloustian K, Martin J.

BMC Cancer. 2017 Sep 2;17(1):611. doi: 10.1186/s12885-017-3549-1.

7.

Kaposi Sarcoma Risk in HIV-Infected Children and Adolescents on Combination Antiretroviral Therapy From Sub-Saharan Africa, Europe, and Asia.

Pediatric AIDS-Defining Cancer Project Working Group for IeDEA Southern Africa, TApHOD, and COHERE in EuroCoord, Rohner E, Schmidlin K, Zwahlen M, Chakraborty R, Clifford G, Obel N, Grabar S, Verbon A, Noguera-Julian A, Collins IJ, Rojo P, Brockmeyer N, Campbell M, Chêne G, Prozesky H, Eley B, Stefan DC, Davidson A, Chimbetete C, Sawry S, Davies MA, Kariminia A, Vibol U, Sohn A, Egger M, Bohlius J.

Clin Infect Dis. 2016 Nov 1;63(9):1245-1253. Epub 2016 Aug 30.

8.

Gender differences in clinical presentation and outcomes of epidemic Kaposi sarcoma in Uganda.

Phipps W, Ssewankambo F, Nguyen H, Saracino M, Wald A, Corey L, Orem J, Kambugu A, Casper C.

PLoS One. 2010 Nov 12;5(11):e13936. doi: 10.1371/journal.pone.0013936.

9.

Comparison of Kaposi Sarcoma Risk in Human Immunodeficiency Virus-Positive Adults Across 5 Continents: A Multiregional Multicohort Study.

AIDS-defining Cancer Project Working Group for IeDEA and COHERE in EuroCoord .

Clin Infect Dis. 2017 Oct 15;65(8):1316-1326. doi: 10.1093/cid/cix480.

PMID:
28531260
10.

Treatment and outcome of AIDS-related Kaposi sarcoma in South Africa, Malawi and Zambia: an international comparison.

Rohner E, Kasaro M, Msadabwe-Chikuni SC, Stinson K, Mohamed Z, Tweya H, Egger M, Bohlius J.

Pan Afr Med J. 2017 Nov 24;28:261. doi: 10.11604/pamj.2017.28.261.11300. eCollection 2017.

11.

Association of CD4+ T-cell Count, HIV-1 RNA Viral Load, and Antiretroviral Therapy With Kaposi Sarcoma Risk Among HIV-infected Persons in the United States and Canada.

Dubrow R, Qin L, Lin H, Hernández-Ramírez RU, Neugebauer RS, Leyden W, Althoff KN, Achenbach CJ, Hessol NA, Modur SP, DʼSouza G, Bosch RJ, Grover S, Horberg MA, Kitahata MM, Mayor AM, Novak RM, Rabkin CS, Sterling TR, Goedert JJ, Justice AC, Engels EA, Moore RD, Silverberg MJ; North American AIDS Cohort Collaboration on Research and Design of the International Epidemiologic Databases to Evaluate AIDS.

J Acquir Immune Defic Syndr. 2017 Aug 1;75(4):382-390. doi: 10.1097/QAI.0000000000001394.

12.

Treatment response and mortality among patients starting antiretroviral therapy with and without Kaposi sarcoma: a cohort study.

Maskew M, Fox MP, van Cutsem G, Chu K, Macphail P, Boulle A, Egger M, Africa FI.

PLoS One. 2013 Jun 5;8(6):e64392. doi: 10.1371/journal.pone.0064392. Print 2013.

13.

Clinical outcomes of HIV-infected patients with Kaposi's sarcoma receiving nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy in Uganda.

Asiimwe F, Moore D, Were W, Nakityo R, Campbell J, Barasa A, Mermin J, Kaharuza F.

HIV Med. 2012 Mar;13(3):166-71. doi: 10.1111/j.1468-1293.2011.00955.x. Epub 2011 Nov 24.

14.

AIDS-related cancer and severity of immunosuppression in persons with AIDS.

Biggar RJ, Chaturvedi AK, Goedert JJ, Engels EA; HIV/AIDS Cancer Match Study.

J Natl Cancer Inst. 2007 Jun 20;99(12):962-72. Epub 2007 Jun 12.

PMID:
17565153
15.

Kaposi sarcoma incidence and survival among HIV-infected homosexual men after HIV seroconversion.

Lodi S, Guiguet M, Costagliola D, Fisher M, de Luca A, Porter K; CASCADE Collaboration.

J Natl Cancer Inst. 2010 Jun 2;102(11):784-92. doi: 10.1093/jnci/djq134. Epub 2010 May 4.

16.

Cancer risk in people infected with human immunodeficiency virus in the United States.

Engels EA, Biggar RJ, Hall HI, Cross H, Crutchfield A, Finch JL, Grigg R, Hylton T, Pawlish KS, McNeel TS, Goedert JJ.

Int J Cancer. 2008 Jul 1;123(1):187-94. doi: 10.1002/ijc.23487.

17.

Trends in the clinical characteristics of HIV-infected patients initiating antiretroviral therapy in Kenya, Uganda and Tanzania between 2002 and 2009.

Geng EH, Hunt PW, Diero LO, Kimaiyo S, Somi GR, Okong P, Bangsberg DR, Bwana MB, Cohen CR, Otieno JA, Wabwire D, Elul B, Nash D, Easterbrook PJ, Braitstein P, Musick BS, Martin JN, Yiannoutsos CT, Wools-Kaloustian K.

J Int AIDS Soc. 2011 Sep 28;14:46. doi: 10.1186/1758-2652-14-46.

18.

Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy.

Clifford GM, Polesel J, Rickenbach M, Dal Maso L, Keiser O, Kofler A, Rapiti E, Levi F, Jundt G, Fisch T, Bordoni A, De Weck D, Franceschi S; Swiss HIV Cohort.

J Natl Cancer Inst. 2005 Mar 16;97(6):425-32.

PMID:
15770006
19.

Frequency and impact of suboptimal immune recovery on first-line antiretroviral therapy within the International Epidemiologic Databases to Evaluate AIDS in East Africa.

Nakanjako D, Kiragga AN, Musick BS, Yiannoutsos CT, Wools-Kaloustian K, Diero L, Oyaro P, Lugina E, Ssali JC, Kambugu A, Easterbrook P.

AIDS. 2016 Jul 31;30(12):1913-22. doi: 10.1097/QAD.0000000000001085.

20.

Changing Incidence and Risk Factors for Kaposi Sarcoma by Time Since Starting Antiretroviral Therapy: Collaborative Analysis of 21 European Cohort Studies.

Cancer Project Working Group for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study in EuroCoord.

Clin Infect Dis. 2016 Nov 15;63(10):1373-1379. Epub 2016 Aug 17.

Supplemental Content

Support Center